| Pig liver sausage as a source of hepatitis E virus transmission to humans P Colson, P Borentain, B Queyriaux, M Kaba, V Moal, P Gallian, L Heyries, ... The Journal of infectious diseases 202 (6), 825-834, 2010 | 810 | 2010 |
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma … V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ... The Lancet Oncology 18 (12), 1624-1636, 2017 | 798 | 2017 |
| Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial JM Perarnau, A Le Gouge, C Nicolas, L d’Alteroche, P Borentain, F Saliba, ... Journal of hepatology 60 (5), 962-968, 2014 | 235 | 2014 |
| Treatment of severe acute hepatitis E by ribavirin R Gerolami, P Borentain, F Raissouni, A Motte, C Solas, P Colson Journal of clinical virology 52 (1), 60-62, 2011 | 204 | 2011 |
| Autochthonous infections with hepatitis E virus genotype 4, France P Colson, P Romanet, V Moal, P Borentain, R Purgus, A Benezech, ... Emerging infectious diseases 18 (8), 1361, 2012 | 138 | 2012 |
| Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients C Charpin, S Guis, P Colson, P Borentain, JP Mattéi, P Alcaraz, ... Arthritis research & therapy 11, 1-5, 2009 | 124 | 2009 |
| Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers P Colson, P Borentain, A Motte, M Henry, V Moal, D Botta-Fridlund, ... Virology 367 (1), 30-40, 2007 | 119 | 2007 |
| Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg‐negative and anti‐HBc antibodies‐positive patients undergoing chemotherapy and/or … P Borentain, P Colson, D Coso, E Bories, A Charbonnier, AM Stoppa, ... Journal of viral hepatitis 17 (11), 807-815, 2010 | 116 | 2010 |
| Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota L Wrzosek, D Ciocan, P Borentain, M Spatz, V Puchois, C Hugot, ... Scientific reports 8 (1), 6854, 2018 | 111 | 2018 |
| The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial C Bureau, D Thabut, C Jezequel, I Archambeaud, L D’alteroche, ... Annals of internal medicine 174 (5), 633-640, 2021 | 109 | 2021 |
| Long‐term outcome in liver transplantation candidates with portopulmonary hypertension L Savale, C Sattler, A Coilly, F Conti, S Renard, C Francoz, H Bouvaist, ... Hepatology 65 (5), 1683-1692, 2017 | 91 | 2017 |
| Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy YW Huang, SC Lin, SC Wei, JT Hu, HY Chang, SH Huang, DS Chen, ... Antiviral therapy 18 (7), 877-884, 2013 | 66* | 2013 |
| Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir S Renard, P Borentain, E Salaun, S Benhaourech, B Maille, A Darque, ... Chest 149 (3), e69-e73, 2016 | 62 | 2016 |
| DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients P Borentain, V Gérolami, P Ananian, S Garcia, A Noundou, ... European journal of cancer 43 (17), 2479-2486, 2007 | 48 | 2007 |
| Entecavir as a first‐line treatment for HBV reactivation following polychemotherapy for lymphoma P Colson, P Borentain, D Coso, C Chabannon, C Tamalet, R Gérolami British journal of haematology 143 (1), 148-150, 2008 | 44 | 2008 |
| Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases R Gerolami, M Bourliere, P Colson, P Halfon, P Borentain, M Henry, ... Antiviral therapy 11 (8), 1103-1106, 2006 | 44 | 2006 |
| The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement P Borentain, J Soussan, N Resseguier, D Botta-Fridlund, JC Dufour, ... Diagnostic and Interventional Imaging 97 (6), 643-650, 2016 | 41 | 2016 |
| Introducing α (1, 2)‐linked fucose into hepatocarcinoma cells inhibits vasculogenesis and tumor growth S Mathieu, R Gerolami, J Luis, S Carmona, O Kol, L Crescence, S Garcia, ... International journal of cancer 121 (8), 1680-1689, 2007 | 41 | 2007 |
| Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis P Borentain, S Carmona, S Mathieu, E Jouve, A El-Battari, R Gérolami Cancer chemotherapy and pharmacology 77, 847-856, 2016 | 40 | 2016 |
| Hepatocellular carcinoma complicating hepatitis E virus–related cirrhosis P Borentain, P Colson, E Bolon, P Gauchez, D Coso, R Gérolami Hepatology 67 (1), 446-448, 2018 | 34 | 2018 |
